2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

2:30PM-4:00PM: Abstract Number: 943

Efficacy and Safety of IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever Who Underwent Kidney Transplantation

Miscellaneous Rheumatic and Inflammatory Diseases I

2:30PM-4:00PM: Abstract Number: 959

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 976

Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan

Vasculitis I: Novel Approaches to Therapy

2:30PM-4:00PM: Abstract Number: 933

Erosion Patterns in Seropositive and Seronegative Rheumatoid Arthritis: A Joint-By-Joint Approach

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 915

Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface

B Cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 950

Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 982

High Financial Strain, but Not Poverty or Lower Education, Increases the Risk of Incident Depression in Systemic Lupus Erythematosus (SLE)

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 932

High Symptom Prevalence and Under-Utilisation of Palliative Care at End-of-Life of Patients with Systemic Rheumatic Diseases

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 930

How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 919

IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice

B Cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 926

Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 957

International Patient and Physician Consensus on Psoriatic Arthritis Outcomes for Clinical Trials

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 924

Intestinal Dysbiosis Influences Gut-Joint Lymphocyte Trafficking

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 934

Magnetic Resonance Imaging (MRI) Joint Space Narrowing Is an Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 975

Maintenance Therapy Improves Long-Term Outcomes in Patients with Primary Angiitis of the Central Nervous System

Vasculitis I: Novel Approaches to Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].